This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-23. Anything still debated is marked as such rather than presented as settled.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
== History == The early 19th century witnessed a sharp increase in the demand for natural ice during the summer months, particularly among breweries producing lager. Due to the advent of railways and steam ships, natural ice was able to be transported efficiently and thus became more readily attainable. To meet the demand for ice, suppliers began investing in methods of producing ice by artificial means. Though it was first documented by Oliver Evans, it was Jacob Perkins, an American working in England, who first patented a machine using the vapour-compression cycle to produce a cooling effect in 1835. In 1855, the first industrial-scale compression machines were developed by James Harrison. Following this, Ferdinand Carré invented the absorption device in 1859. This was then rendered obsolete by the invention of the vapor compression refrigerator invented by French engineer Charles Tellier in 1885, the basic principles of which are used today. To support the development of refrigeration technologies and in view of the economic development potential they represented, the IIR was created in several stages:
Due to the reduced water content of the freeze-dried foods that inhibit the growth of microorganisms and prevent enzymatic chemical reactions, these foods are considered shelf-stable and can be kept safe from spoilage for years by preventing the reabsorption of moisture. Freeze-dried foods can be stored at room temperature without the need for refrigeration. Although uncommon compared to most applications, sometimes a seasoning solution is sprayed directly onto ramen noodles to enhance their flavor, prior to being packaged. Powder seasoning packets may also contain anticaking agents and flow agents to prevent the product from clumping into a solid mass.
Alejandro Zaffaroni (February 27, 1923 – March 1, 2014) was a Uruguayan serial entrepreneur who was responsible for founding several biotechnology companies in Silicon Valley. Products that he was involved in developing include the birth control pill, the nicotine patch, corticosteroids, and the DNA microarray.
While these remains have been extraordinarily well preserved, the embalming fluids and methods used are unknown. In Europe the ancient practice of artificial preservation had become widespread by about 500 CE. The period of the Middle Ages and the Renaissance is known as the anatomists' period of embalming and is characterized by an increased influence of scientific developments in medicine and the need for bodies for dissection purposes. Early methods used are documented by contemporary physicians such as Peter Forestus (1522–1597) and Ambroise Pare (1510–1590). The first attempts to inject the vascular system were made by Alessandra Giliani, who died in 1326. Various attempts and procedures have been reported by Leonardo da Vinci (1452–1519), Jacobus Berengar (1470–1550), Bartholomeo Eustachius (1520–1574), Reinier de Graaf (1641–1673), Jan Swammerdam (1637–1680), and Frederik Ruysch (1638–1731).
== Scoring == The LP-IR score ranges from 0 (most insulin-sensitive) to 100 (most insulin-resistant). It's calculated by weighting the six parameters, which are more strongly correlated with insulin resistance than individual lipid measures like triglycerides or HDL cholesterol alone. Results are typically categorized:
Sources: en.wikipedia.org
== Personal life == Studied a Bachelor of Business at RMIT University and currently lives in Sydney with his wife Kirsty. David and Kirsty have a two-year-old daughter, Matilda and will soon have a second child. David completed postgraduate studies at Sydney University and now works for Deloitte as a senior analyst.
===== Pharmacokinetics ===== Cyproterone acetate is mainly orally administered to the body, and it has a half-life of 1.8 days. After metabolism, its metabolites are predominantly excreted via faeces.
=== Ojibwe === The longest word in the Ojibwe language is miinibaashkiminasiganibiitoosijiganibadagwiingweshiganibakwezhigan (66 letters), meaning "blueberry pie". This literally translates to "blueberry cooked to jellied preserve that lies in layers in which the face is covered in bread".
== Types == In the broadest definition, an organelle is any part of the cell that acts as a distinct functional unit. This includes membrane-bound as well as non-membrane-bound, or membrane-less organelles. In a more restrictive definition, only membrane-bound ones are included. In the most restrictive definition, only the endosymbiotic membrane-bound ones are included. The membrane-bound organelles include the endosymbiotic (mitochondria and plastids) and components formed by the endomembrane system such as the lysosome. An endomembrane system and mitochondria are found in almost all eukaryotes. Plants, algae, and some protists additionally have chloroplasts. A very small minority of bacteria also have a sort-of endomembrane system. The membrane-less organelles (MLOs), also called biomolecular complexes, are large assemblies of macromolecules that carry out particular and specialized functions, but are membrane-less. Many of these are referred to as "proteinaceous organelles" as their main structure is made of proteins. MLOs include:
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.